Cytokinetics launches Aspen-HCM real-world study evaluating Myqorzo in symptomatic obstructive hypertrophic cardiomyopathy
CYTK•Cytokinetics launched Aspen-HCM, a real-world study evaluating Myqorzo (aficamten) in symptomatic obstructive hypertrophic cardiomyopathy.
1. Study launch
Cytokinetics launched Aspen-HCM, a real-world study evaluating Myqorzo (aficamten) in symptomatic obstructive hypertrophic cardiomyopathy.
